O6-Benzylguanine and its role in chemotherapy

M. Eileen Dolan, Anthony Pegg

Research output: Contribution to journalReview article

214 Citations (Scopus)

Abstract

The presence of the DNA repair protein, O6-alkylguanine-DNA alkyltransferase (AGT) in tumor cells is a significant source of resistance to chemotherapeutic alkylnitrosoureas and alkyltriazenes. O6-Benzylguanine provides a means to effectively inactivate the AGT protein and increase the chemotherapeutic effectiveness of chloroethylating and methylating agents in vitro and in human tumor xenograft models. Phase I clinical trials of the combination of O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea are ongoing. Efforts directed at overcoming potential enhanced hematopoietic toxicity and mutagenicity have included the use of gene therapy to express an alkyltransferase gene in the relevant marrow stem cells. Altered AGT proteins resistant to O6-benzylguanine generated from point mutations in the mammalian alkyltransferase gene have been expressed in animal models using retroviral transduction techniques, It is anticipated that the successful application of this approach in humans may provide a means to increase the therapeutic index of O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea.

Original languageEnglish (US)
Pages (from-to)837-847
Number of pages11
JournalClinical Cancer Research
Volume3
Issue number6
StatePublished - Jun 1 1997

Fingerprint

Alkyl and Aryl Transferases
Drug Therapy
Carmustine
Clinical Trials, Phase I
Proteins
Point Mutation
Heterografts
DNA Repair
Genetic Therapy
Genes
Neoplasms
Stem Cells
Animal Models
Bone Marrow
O(6)-benzylguanine
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Dolan, M. Eileen ; Pegg, Anthony. / O6-Benzylguanine and its role in chemotherapy. In: Clinical Cancer Research. 1997 ; Vol. 3, No. 6. pp. 837-847.
@article{26131675dd1e4ef3868e766559bf5793,
title = "O6-Benzylguanine and its role in chemotherapy",
abstract = "The presence of the DNA repair protein, O6-alkylguanine-DNA alkyltransferase (AGT) in tumor cells is a significant source of resistance to chemotherapeutic alkylnitrosoureas and alkyltriazenes. O6-Benzylguanine provides a means to effectively inactivate the AGT protein and increase the chemotherapeutic effectiveness of chloroethylating and methylating agents in vitro and in human tumor xenograft models. Phase I clinical trials of the combination of O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea are ongoing. Efforts directed at overcoming potential enhanced hematopoietic toxicity and mutagenicity have included the use of gene therapy to express an alkyltransferase gene in the relevant marrow stem cells. Altered AGT proteins resistant to O6-benzylguanine generated from point mutations in the mammalian alkyltransferase gene have been expressed in animal models using retroviral transduction techniques, It is anticipated that the successful application of this approach in humans may provide a means to increase the therapeutic index of O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea.",
author = "Dolan, {M. Eileen} and Anthony Pegg",
year = "1997",
month = "6",
day = "1",
language = "English (US)",
volume = "3",
pages = "837--847",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "6",

}

O6-Benzylguanine and its role in chemotherapy. / Dolan, M. Eileen; Pegg, Anthony.

In: Clinical Cancer Research, Vol. 3, No. 6, 01.06.1997, p. 837-847.

Research output: Contribution to journalReview article

TY - JOUR

T1 - O6-Benzylguanine and its role in chemotherapy

AU - Dolan, M. Eileen

AU - Pegg, Anthony

PY - 1997/6/1

Y1 - 1997/6/1

N2 - The presence of the DNA repair protein, O6-alkylguanine-DNA alkyltransferase (AGT) in tumor cells is a significant source of resistance to chemotherapeutic alkylnitrosoureas and alkyltriazenes. O6-Benzylguanine provides a means to effectively inactivate the AGT protein and increase the chemotherapeutic effectiveness of chloroethylating and methylating agents in vitro and in human tumor xenograft models. Phase I clinical trials of the combination of O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea are ongoing. Efforts directed at overcoming potential enhanced hematopoietic toxicity and mutagenicity have included the use of gene therapy to express an alkyltransferase gene in the relevant marrow stem cells. Altered AGT proteins resistant to O6-benzylguanine generated from point mutations in the mammalian alkyltransferase gene have been expressed in animal models using retroviral transduction techniques, It is anticipated that the successful application of this approach in humans may provide a means to increase the therapeutic index of O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea.

AB - The presence of the DNA repair protein, O6-alkylguanine-DNA alkyltransferase (AGT) in tumor cells is a significant source of resistance to chemotherapeutic alkylnitrosoureas and alkyltriazenes. O6-Benzylguanine provides a means to effectively inactivate the AGT protein and increase the chemotherapeutic effectiveness of chloroethylating and methylating agents in vitro and in human tumor xenograft models. Phase I clinical trials of the combination of O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea are ongoing. Efforts directed at overcoming potential enhanced hematopoietic toxicity and mutagenicity have included the use of gene therapy to express an alkyltransferase gene in the relevant marrow stem cells. Altered AGT proteins resistant to O6-benzylguanine generated from point mutations in the mammalian alkyltransferase gene have been expressed in animal models using retroviral transduction techniques, It is anticipated that the successful application of this approach in humans may provide a means to increase the therapeutic index of O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea.

UR - http://www.scopus.com/inward/record.url?scp=0030608633&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030608633&partnerID=8YFLogxK

M3 - Review article

C2 - 9815757

AN - SCOPUS:0030608633

VL - 3

SP - 837

EP - 847

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 6

ER -